journal
MENU ▼
Read by QxMD icon Read
search

Drugs

journal
https://read.qxmd.com/read/30993651/lenvatinib-a-review-in-hepatocellular-carcinoma
#1
Zaina T Al-Salama, Yahiya Y Syed, Lesley J Scott
Lenvatinib (Lenvima® ) is an oral small molecule inhibitor of multiple receptor tyrosine kinases, and is approved for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) in the USA, EU, Japan and China. The approval of lenvatinib was based on results of the randomized, open-label, multinational, non-inferiority phase III REFLECT trial in patients with unresectable HCC, who had not received treatment for advanced disease. In REFLECT, lenvatinib was non-inferior, but not superior, to sorafenib (current standard of care) for overall survival (OS)...
April 16, 2019: Drugs
https://read.qxmd.com/read/30989634/efficacy-and-safety-of-mipomersen-a-systematic-review-and-meta-analysis-of-randomized-clinical-trials
#2
REVIEW
Federica Fogacci, Nicola Ferri, Peter P Toth, Massimiliano Ruscica, Alberto Corsini, Arrigo F G Cicero
AIM: Our aim was to assess the efficacy and safety of mipomersen through a systematic review of the literature and a meta-analysis of the available clinical studies. METHODS: A systematic literature search in SCOPUS, PubMed Medline, ISI Web of Science and Google Scholar databases was conducted up to January 20, 2019, in order to identify clinical trials assessing the effect of mipomersen on lipoproteins, and the safety profile of mipomersen. Effect sizes for lipid changes were expressed as weighted mean differences (WMD) and 95% confidence intervals (CI)...
April 15, 2019: Drugs
https://read.qxmd.com/read/30982161/targeting-%C3%AE-synuclein-in-parkinson-s-disease-progress-towards-the-development-of-disease-modifying-therapeutics
#3
Daniel Savitt, Joseph Jankovic
Parkinson's disease (PD), the second most common neurodegenerative movement disorder, is characterized by progressive motor and non-motor symptoms [1]. Despite treatment with pharmacologic and surgical therapies, the disease will continue to relentlessly advance. Hence, there is a great deal of interest in potential disease-modifying therapies with the hope that the neurodegenerative process can be slowed or halted. The purpose of this review is to highlight the role toxic α-synuclein (α-syn) plays in PD pathogenesis and critically review the relevant literature about therapeutic modalities targeting α-syn...
April 13, 2019: Drugs
https://read.qxmd.com/read/30982160/the-unique-pharmacological-and-pharmacokinetic-profile-of-teneligliptin-implications-for-clinical-practice
#4
REVIEW
Antonio Ceriello, Valeria De Nigris, Hiroaki Iijima, Takahiro Matsui, Maki Gouda
Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan and Korea and is being researched in several countries. Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor with a t½ of approximately 24 h and unique pharmacokinetic properties: it is metabolized by cytochrome P450 (CYP) 3A4 and flavin-containing monooxygenase 3 (FMO3), or excreted from the kidney in an unchanged form. Because of its multiple elimination pathways, dose adjustment is not needed in patients with hepatic or renal impairment, and it is considered to have a low potential for drug-drug interactions...
April 13, 2019: Drugs
https://read.qxmd.com/read/30977103/correction-to-eravacycline-a-review-in-complicated-intra-abdominal-infections
#5
Lesley J Scott
The article Eravacycline: A Review in Complicated Intra-Abdominal Infections, written by Lesley J. Scott, was originally published Online First without open access.
April 11, 2019: Drugs
https://read.qxmd.com/read/30972661/the-clinician-s-guide-to-proton-pump-inhibitor-related-adverse-events
#6
Evan Elias, Laura E Targownik
A substantial volume of literature exists linking proton pump inhibitor (PPI) use with a multitude of serious adverse events. There is uncertainty, however, over whether these associations are clinically important. Excessive concern about PPI-related adverse events may leave patients at risk of harm by leaving acid-related upper gastrointestinal disease untreated. Conversely, the risk of treatments may outweigh the benefits if any of the purported adverse events are directly caused by PPI use; this is of particular concern where indications for PPI use are not present...
April 10, 2019: Drugs
https://read.qxmd.com/read/30972660/new-drugs-for-multidrug-resistant-gram-negative-organisms-time-for-stewardship
#7
Shio-Shin Jean, Ian M Gould, Wen-Sen Lee, Po-Ren Hsueh
A gradual rise in drug-resistant trends among Gram-negative organisms, especially carbapenem-resistant (CR) Enterobacteriaceae (CRE), CR-Pseudomonas aeruginosa, and extensively-drug-resistant (XDR) Acinetobacter baumannii, poses an enormous threat to healthcare systems worldwide. In the last decade, many pharmaceutical companies have devoted enormous resources to the development of new potent antibiotics against XDR Gram-negative pathogens, particularly CRE. Some of these novel antibiotics against CRE strains are β-lactam/β-lactamase-inhibitor combination agents, while others belong to the non-β-lactam class...
April 10, 2019: Drugs
https://read.qxmd.com/read/30968290/are-all-dopamine-agonists-essentially-the-same
#8
Margherita Torti, Daniele Bravi, Laura Vacca, Fabrizio Stocchi
Dopamine agonists (DAs) represent an excellent treatment option for patients with Parkinson's disease, in both the early and advanced stages of the disease, improving motor symptoms, lowering the incidence of motor complications, and addressing several non-motor symptoms. Indeed, each of these compounds have different pharmacokinetic and pharmacodynamic properties, resulting in a unique efficacy and safety profile. Comorbidities, prominent non-motor symptoms and individual subjects' clinical characteristics should guide the choice of a specific DA, allowing better management of the patient by optimizing the DA benefit/risk ratio...
April 9, 2019: Drugs
https://read.qxmd.com/read/30968289/targeting-egfr-and-ras-raf-signaling-in-the-treatment-of-metastatic-colorectal-cancer-from-current-treatment-strategies-to-future-perspectives
#9
REVIEW
Takuro Mizukami, Naoki Izawa, Takako Eguchi Nakajima, Yu Sunakawa
The epidermal growth factor receptor (EGFR) and RAS/RAF signaling pathway plays pivotal roles in tumor progression via proliferation, survival, invasion, and immune evasion. Two anti-EGFR monoclonal antibodies, cetuximab and panitumumab, have become essential components in the treatment of patients with metastatic colorectal cancer (mCRC). Treatment with these anti-EGFR antibodies has shown definite benefits when administered in all treatment lines and is strongly recommended as the preferred regimen to prolong survival, especially when administered in the first- and third-lines...
April 9, 2019: Drugs
https://read.qxmd.com/read/30963509/drug-resistance-during-hiv-pre-exposure-prophylaxis
#10
Kevin M Gibas, Polly van den Berg, Victoria E Powell, Douglas S Krakower
Clinical studies have demonstrated that use of tenofovir disoproxil fumarate with or without emtricitabine as antiretroviral pre-exposure prophylaxis (PrEP) can decrease the risk of human immunodeficiency virus (HIV) acquisition when medication adherence is high. However, the potential for PrEP to promote antiretroviral resistance remains an important public health consideration. We performed a search of the medical literature to identify studies that address HIV drug resistance during PrEP use. In this review, we summarize findings about emergent drug resistance during clinical trials of PrEP, case reports of seroconversions in patients adherent to PrEP, and animal studies of PrEP effectiveness against drug-resistant viral strains...
April 8, 2019: Drugs
https://read.qxmd.com/read/30941607/distinct-profiles-on-subjective-and-objective-adherence-measures-in-patients-prescribed-antidepressants
#11
Hans Wouters, Didi Rhebergen, Marcia Vervloet, Antoine Egberts, Katja Taxis, Liset van Dijk, Helga Gardarsdottir
OBJECTIVE: A recurrent observation is that associations between self-reported and objective medication adherence measures are often weak to moderate. Our aim was therefore to identify patients with different profiles on self-reported and objective adherence measures. STUDY DESIGN AND SETTING: This was an observational study of 221 community pharmacy patients who were dispensed antidepressants. Adherence profiles were estimated with Latent Profile Analysis (LPA) using data on self-reported adherence (Medication Adherence Rating Scale) complemented with data on medication beliefs (perceived necessity and concerns measured with the Beliefs about Medicines Questionnaire) and data from objective adherence measures (electronic monitoring of medication taking and the Medication Possession Ratio calculated from pharmacy dispensing data)...
April 3, 2019: Drugs
https://read.qxmd.com/read/30941606/correction-to-amikacin-liposome-inhalation-suspension-a-review-in-mycobacterium-avium-complex-lung-disease
#12
Matt Shirley
The article Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.
April 3, 2019: Drugs
https://read.qxmd.com/read/30941605/correction-to-triamcinolone-aceonide-extended-release-a-review-in-osteoarthritis-pain-of-the-knee
#13
Julia Paik, Sean T Duggan, Susan J Keam
An Online First version of this article was made available online at.
April 3, 2019: Drugs
https://read.qxmd.com/read/30937733/relugolix-first-global-approval
#14
Anthony Markham
The orally active nonpeptide gonadotropin-releasing hormone (GnRH)-receptor antagonist relugolix (Relumina) is being developed by Takeda and ASKA Pharmaceutical as a treatment for various sex hormone related disorders. Relugolix was recently approved for marketing in Japan as a treatment for symptoms associated with uterine fibroids, and studies evaluating the efficacy of the drug as treatment for endometriosis-associated pain and prostate cancer are currently underway. This article summarizes the milestones in the development of relugolix leading to this first approval for the treatment of symptoms associated with uterine fibroids...
April 1, 2019: Drugs
https://read.qxmd.com/read/30927162/correction-to-revefenacin-first-global-approval
#15
Young-A Heo
The article Revefenacin: First Global Approval, written by Young-A Heo, was originally published Online First without open access. After publication in volume 79, issue 1, pages 85-91, Mylan Inc. (Canonsburg, Pennsylvania, USA) and Theravance Biopharma US, Inc. (South San Francisco, California, USA) requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Mylan Inc. (Canonsburg, Pennsylvania, USA) and Theravance Biopharma US, Inc. (South San Francisco, California, USA)...
March 29, 2019: Drugs
https://read.qxmd.com/read/30919305/comment-on-achieving-glycaemic-control-with-concentrated-insulin-in-patients-with-type-2-diabetes
#16
LETTER
Stephen Gough
No abstract text is available yet for this article.
March 27, 2019: Drugs
https://read.qxmd.com/read/30919304/authors-reply-to-gough-achieving-glycaemic-control-with-concentrated-insulin-in-patients-with-type-2-diabetes
#17
LETTER
Sudesna Chatterjee, Kamlesh Khunti, Melanie Davies
No abstract text is available yet for this article.
March 27, 2019: Drugs
https://read.qxmd.com/read/30905034/contemporary-options-for-the-management-of-motor-complications-in-parkinson-s-disease-updated-clinical-review
#18
Verónica Cabreira, Patrício Soares-da-Silva, João Massano
Parkinson's disease (PD) is a chronic, progressive condition affecting around 1% of the population older than 60 years. Upon long-term treatment with levodopa, the mainstay of treatment in PD, most patients, especially younger ones exposed to higher doses, will experience symptoms related to end-of-dose deterioration, peak-dose dyskinesias, and other motor fluctuations. Therapeutic strategies are grounded on modification of oral levodopa pharmacokinetics to extend levodopa benefit and development of new routes of drug delivery (e...
March 23, 2019: Drugs
https://read.qxmd.com/read/30905033/direct-oral-anticoagulants-in-the-prevention-and-treatment-of-venous-thromboembolism-in-patients-with-cancer-new-insights-from-randomized-controlled-trials
#19
Cristhiam M Rojas-Hernandez, Thein Hlaing Oo
Cancer accounts for 20% of all venous thromboembolism (VTE) worldwide and cancer patients are at four- to sevenfold increased risk of thrombosis compared to non-cancer patients. VTE is also a morbid complication of cancer and its incidence is rising. Thrombosis is also a second leading cause of death in cancer patients. The standard of care management for the prevention and treatment of cancer-associated thrombosis (CAT) remains the administration of low-molecular-weight heparins (LMWHs). In the last decade, five direct oral anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban, have been approved for the treatment and prevention of VTE in the general patient population...
March 23, 2019: Drugs
https://read.qxmd.com/read/30903610/correction-to-bictegravir-emtricitabine-tenofovir-alafenamide-a-review-in-hiv-1-infection
#20
Emma D Deeks
The article Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection, written by Emma D. Deeks, was originally published Online First without open access. After publication in volume 78, issue 17, pages 1817-1828 Gilead Sciences requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Gilead Sciences. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons...
March 22, 2019: Drugs
journal
journal
26573
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"